Amylin Pharmaceuticals To Present New Data From Broad Diabetes And Obesity Programs At ADA 2007

Amylin Pharmaceuticals,
Inc. (Nasdaq: AMLN) today announced that data featuring its approved
diabetes drugs, BYETTA(R) (exenatide) injection and SYMLIN(R) (pramlintide
acetate) injection, and its pipeline candidates will be presented at the
American Diabetes Association’s (ADA) 67th Annual Scientific Sessions being
held in Chicago, IL from June 22 to 26. The company will also host an
investor presentation during the meeting that will be available by webcast.
ADA is one of the largest scientific meetings for endocrinologists and
other health care professionals involved in diabetes research and delivery
of diabetes care.

Data from several studies will be highlighted in oral presentations and
poster sessions that will provide insight into Amylin’s approved diabetes
drugs, BYETTA and SYMLIN and the company’s research and development
programs. Additional information will also be presented during two symposia
focused on the multihormonal approach to treatment of diabetes and obesity,
and the role of incretin-based therapies in type 2 diabetes.

“Our activities at this year’s ADA will reinforce the important
therapeutic benefits of BYETTA and SYMLIN and focus on novel peptide
hormones and their potential to treat obesity,” said Daniel M. Bradbury,
President and Chief Executive Officer of Amylin Pharmaceuticals, Inc. “We
are dedicated to bringing innovative medicines with life-changing
therapeutic potential to patients. Our broad clinical program is designed
to continue transforming the care of diabetes and obesity.”

KEY AMYLIN ABSTRACTS BEING PRESENTED AT ADA:

1. Oral: “Less Hypoglycemia with Exenatide Versus Insulin Glargine,
Despite Similar HbA1c Improvement in Patients with T2DM Adjunctively
Treated with Metformin” will be presented by Michael E. Trautmann, M.D.
on Sunday, June 24 at 3:45 PM CT (4:45 PM ET).

2. Oral: “Exenatide Maintained Glycemic Control with Associated Weight
Reduction Over Three Years in Patients with Type 2 Diabetes” will be
presented by John B. Buse, M.D. on Monday, June 25 at 3:15 PM CT
(4:15 PM ET).

3. Poster: “Improvements in Cardiovascular Risk Factors Accompanied
Improved Glycemic Control and Weight Reduction in Patients with Type 2
Diabetes Treated with Exenatide for 3.5 y” will be presented by David
Kendall, M.D. during a poster session on Sunday, June 24 at 12:00 PM CT
(1:00 PM ET).

4. Poster: “Pramlintide Improved Glycemic Control without Increased Risk
of Hypoglycemia in Patients with Type 2 Diabetes Using Basal Insulin”
will be presented by Karen Lutz, Ph.D. during a poster session on
Sunday, June 24 at 12:00 PM CT (1:00 PM ET).

5. Oral: “Responsiveness to Leptin Restored by Amylin in Diet Induced
Obese (DIO) Rats: Magnitude and Mechanisms of Synergy” will be
presented by Jonathan Roth, Ph.D. on Monday, June 25 at 3:45 PM CT
(4:45 PM ET).

6. Oral: “Sustained Weight Loss Following 1-y Pramlintide Treatment as an
Adjunct to Lifestyle Intervention in Obesity” will be presented by
Steven Smith, M.D. on Monday, June 25 at 5:30 PM CT (6:30 PM ET).

A full list of all Amylin abstracts being presented at ADA is available
at: scientificsessions.diabetes.

FEATURED SYMPOSIA

1. “The Diabetes-Obesity Continuum: The Growing Body of Evidence for a
Multihormonal Approach to Treatment.” This medical education symposium
will help healthcare providers understand the potential of
multihormonal treatment approaches for diabetes and obesity. The event
will be chaired by Carol Hatch Wysham, M.D. on Sunday, June 24 at 5:30
AM CT (6:30 AM ET). This symposium is supported by an unrestricted
educational grant from Amylin Pharmaceuticals.

2. “The Role of Incretin-Based Therapies: Reconstructing Treatment
Approaches in Type 2 Diabetes.” This medical education symposium will
help healthcare providers understand the role of incretin-based
therapies in relation to type 2 diabetes. The event will be chaired by
Bernard Zinman, M.D. on Monday, June 25 at 5:30 AM CT (6:30 AM ET).
This symposium is supported by an unrestricted educational grant from
Amylin Pharmaceuticals and Eli Lilly and Co.

Amylin will also conduct a webcast for investors to review the
information presented at ADA on Sunday, June 24 at 7:30 PM CT (8:30 PM ET).
The live presentation will be webcast, and a recording will be made
available following the event. The webcast and recording will be accessible
through Amylin’s corporate Web site, located at amylin. To
access the live webcast, please log on to Amylin’s site approximately 15
minutes prior to the presentation to register and download any necessary
audio software.

More information about ADA can be found at
scientificsessions.diabetes.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to
improving lives through the discovery, development and commercialization of
innovative medicines. Amylin has developed and gained approval for two
first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate)
injection and BYETTA(R) (exenatide) injection. Amylin’s research and
development activities leverage the company’s expertise in metabolism to
develop potential therapies to treat diabetes and obesity. Amylin is
located in San Diego, California with over 1,700 employees nationwide. For
more information about Amylin visit amylin.

This press release contains forward-looking statements about Amylin,
which involve risks and uncertainties. Amylin’s actual results could differ
materially from those discussed herein due to a number of risks and
uncertainties, including risks that BYETTA or SYMLIN, and the revenues
Amylin generates from these products, may be affected by competition,
unexpected new data, technical issues, or manufacturing and supply issues;
risks that the results of pre-clinical studies or clinical trials may not
be predictive of future results; risks that our clinical trials will not
start or be completed when planned; risks that the FDA may not approve
Amylin’s regulatory submissions; and risks inherent in the drug development
and commercialization process. Commercial and government reimbursement and
pricing decisions and the pace of market acceptance may also affect the
potential for BYETTA or SYMLIN. These and additional risks and
uncertainties are described more fully in Amylin’s recently filed Form 10-Q. Amylin disclaims any obligation to update these forward-looking statements.

Amylin Pharmaceuticals, Inc.
amylin

View drug information on Byetta; Symlin.

Advertisements
This entry was posted in Uncategorized. Bookmark the permalink.